News

Public · Published

LifeStance Health Q3 revenue beats on clinician growth, lifts FY outlook

LifeStance Health said third-quarter revenue increased 25% and adjusted EBITDA, a measure of operating earnings before certain costs, rose 70%; both exceeded analyst expectations. The company raised its full-year 2026 revenue and adjusted EBITDA outlook, citing higher visit volumes and revenue per visit.

Published:

Updated:

What happened

LifeStance Health said third-quarter revenue increased 25% and adjusted EBITDA, a measure of operating earnings before certain costs, rose 70%; both exceeded analyst expectations. The company raised its full-year 2026 revenue and adjusted EBITDA outlook, citing higher visit volumes and revenue per visit.

Confirmed

Global impact / market context

Higher visit volumes, clinician growth and productivity, and increased revenue per visit supported sales growth. LifeStance said lower center costs as a share of revenue and slower growth in administrative expenses also lifted adjusted EBITDA, suggesting revenue growth is improving operating efficiency.

Analyst inference

The results show growth in both revenue and adjusted EBITDA, while the higher full-year outlook points to management expecting that momentum to continue. The article also reports a buy-leaning analyst consensus, but provides no share-price reaction or evidence of how investors have positioned themselves.

Analyst inference

What to watch

  1. Check whether future reports show visit volumes and clinician numbers continuing to rise, since LifeStance said both helped drive third-quarter revenue growth. Analyst inference
  2. Compare future revenue per visit and center costs as a share of revenue; the company said both contributed to improved adjusted EBITDA performance. Analyst inference
  3. Assess whether full-year 2026 revenue and adjusted EBITDA meet or exceed the raised outlook, since that would test whether recent growth drivers continue. Analyst inference

Evidence

  • Original source link unavailable